Cargando…
A Case Report on Dysgraphia in a Patient Receiving Blinatumomab: Complex Characters Are Easy to Find in a Handwriting Test
Recent advances in chemotherapy have led to the emergence of new types of anticancer agents. With these advances, cases of side effects that have not been witnessed in the past have emerged. The systems of side effect evaluation and their grading have been based on the existing knowledge, such as th...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9229329/ https://www.ncbi.nlm.nih.gov/pubmed/35743996 http://dx.doi.org/10.3390/medicina58060733 |
_version_ | 1784734717459824640 |
---|---|
author | Yamamoto, Yasuto Shimasaki, Takeo Ishigaki, Yasuhito Fujimoto, Shino Takahashi, Yoshimitsu Kimura, Shiori Aijo, Keiko Takayanagi, Mami Mizuta, Shuichi Masauji, Togen Masaki, Yasufumi |
author_facet | Yamamoto, Yasuto Shimasaki, Takeo Ishigaki, Yasuhito Fujimoto, Shino Takahashi, Yoshimitsu Kimura, Shiori Aijo, Keiko Takayanagi, Mami Mizuta, Shuichi Masauji, Togen Masaki, Yasufumi |
author_sort | Yamamoto, Yasuto |
collection | PubMed |
description | Recent advances in chemotherapy have led to the emergence of new types of anticancer agents. With these advances, cases of side effects that have not been witnessed in the past have emerged. The systems of side effect evaluation and their grading have been based on the existing knowledge, such as the CTCAE (Common Terminology Standard for Adverse Events) for evaluating adverse drug reactions in cancer chemotherapy clinical trials. Therefore, new types of side effects may be overlooked or underestimated. Blinatumomab is a bispecific T-cell–engager (BiTE) antibody with specificity for CD19 on B cells and CD3 on T cells. Neurological events, such as neuropathy and encephalopathy, are serious side effects of BiTE antibodies. We encountered a case of a 62-year-old woman who experienced short-term memory impairment and dysgraphia after the first blinatumomab administration for Philadelphia chromosome negative (Ph−) B-cell acute lymphoblastic leukemia (ALL). The CTCAE does not include dysgraphia as a classifier for antibody therapies, such as blinatumomab, and immune effector cell-associated neurotoxicity syndrome, which is defined as a Chimeric antigen receptor T cell therapy-related toxicity; dysgraphia is included in the list of symptoms but is not graded. In this case, the severity of dysgraphia differed depending on the complexity of the letters examined. There is no report that the severity of dysgraphia depends on the letters’ complexity, and therefore, it may be overlooked when using simple letters. We have reported the characteristics of dysgraphia in this case and the differences observed when judging different letters. |
format | Online Article Text |
id | pubmed-9229329 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-92293292022-06-25 A Case Report on Dysgraphia in a Patient Receiving Blinatumomab: Complex Characters Are Easy to Find in a Handwriting Test Yamamoto, Yasuto Shimasaki, Takeo Ishigaki, Yasuhito Fujimoto, Shino Takahashi, Yoshimitsu Kimura, Shiori Aijo, Keiko Takayanagi, Mami Mizuta, Shuichi Masauji, Togen Masaki, Yasufumi Medicina (Kaunas) Case Report Recent advances in chemotherapy have led to the emergence of new types of anticancer agents. With these advances, cases of side effects that have not been witnessed in the past have emerged. The systems of side effect evaluation and their grading have been based on the existing knowledge, such as the CTCAE (Common Terminology Standard for Adverse Events) for evaluating adverse drug reactions in cancer chemotherapy clinical trials. Therefore, new types of side effects may be overlooked or underestimated. Blinatumomab is a bispecific T-cell–engager (BiTE) antibody with specificity for CD19 on B cells and CD3 on T cells. Neurological events, such as neuropathy and encephalopathy, are serious side effects of BiTE antibodies. We encountered a case of a 62-year-old woman who experienced short-term memory impairment and dysgraphia after the first blinatumomab administration for Philadelphia chromosome negative (Ph−) B-cell acute lymphoblastic leukemia (ALL). The CTCAE does not include dysgraphia as a classifier for antibody therapies, such as blinatumomab, and immune effector cell-associated neurotoxicity syndrome, which is defined as a Chimeric antigen receptor T cell therapy-related toxicity; dysgraphia is included in the list of symptoms but is not graded. In this case, the severity of dysgraphia differed depending on the complexity of the letters examined. There is no report that the severity of dysgraphia depends on the letters’ complexity, and therefore, it may be overlooked when using simple letters. We have reported the characteristics of dysgraphia in this case and the differences observed when judging different letters. MDPI 2022-05-29 /pmc/articles/PMC9229329/ /pubmed/35743996 http://dx.doi.org/10.3390/medicina58060733 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Yamamoto, Yasuto Shimasaki, Takeo Ishigaki, Yasuhito Fujimoto, Shino Takahashi, Yoshimitsu Kimura, Shiori Aijo, Keiko Takayanagi, Mami Mizuta, Shuichi Masauji, Togen Masaki, Yasufumi A Case Report on Dysgraphia in a Patient Receiving Blinatumomab: Complex Characters Are Easy to Find in a Handwriting Test |
title | A Case Report on Dysgraphia in a Patient Receiving Blinatumomab: Complex Characters Are Easy to Find in a Handwriting Test |
title_full | A Case Report on Dysgraphia in a Patient Receiving Blinatumomab: Complex Characters Are Easy to Find in a Handwriting Test |
title_fullStr | A Case Report on Dysgraphia in a Patient Receiving Blinatumomab: Complex Characters Are Easy to Find in a Handwriting Test |
title_full_unstemmed | A Case Report on Dysgraphia in a Patient Receiving Blinatumomab: Complex Characters Are Easy to Find in a Handwriting Test |
title_short | A Case Report on Dysgraphia in a Patient Receiving Blinatumomab: Complex Characters Are Easy to Find in a Handwriting Test |
title_sort | case report on dysgraphia in a patient receiving blinatumomab: complex characters are easy to find in a handwriting test |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9229329/ https://www.ncbi.nlm.nih.gov/pubmed/35743996 http://dx.doi.org/10.3390/medicina58060733 |
work_keys_str_mv | AT yamamotoyasuto acasereportondysgraphiainapatientreceivingblinatumomabcomplexcharactersareeasytofindinahandwritingtest AT shimasakitakeo acasereportondysgraphiainapatientreceivingblinatumomabcomplexcharactersareeasytofindinahandwritingtest AT ishigakiyasuhito acasereportondysgraphiainapatientreceivingblinatumomabcomplexcharactersareeasytofindinahandwritingtest AT fujimotoshino acasereportondysgraphiainapatientreceivingblinatumomabcomplexcharactersareeasytofindinahandwritingtest AT takahashiyoshimitsu acasereportondysgraphiainapatientreceivingblinatumomabcomplexcharactersareeasytofindinahandwritingtest AT kimurashiori acasereportondysgraphiainapatientreceivingblinatumomabcomplexcharactersareeasytofindinahandwritingtest AT aijokeiko acasereportondysgraphiainapatientreceivingblinatumomabcomplexcharactersareeasytofindinahandwritingtest AT takayanagimami acasereportondysgraphiainapatientreceivingblinatumomabcomplexcharactersareeasytofindinahandwritingtest AT mizutashuichi acasereportondysgraphiainapatientreceivingblinatumomabcomplexcharactersareeasytofindinahandwritingtest AT masaujitogen acasereportondysgraphiainapatientreceivingblinatumomabcomplexcharactersareeasytofindinahandwritingtest AT masakiyasufumi acasereportondysgraphiainapatientreceivingblinatumomabcomplexcharactersareeasytofindinahandwritingtest AT yamamotoyasuto casereportondysgraphiainapatientreceivingblinatumomabcomplexcharactersareeasytofindinahandwritingtest AT shimasakitakeo casereportondysgraphiainapatientreceivingblinatumomabcomplexcharactersareeasytofindinahandwritingtest AT ishigakiyasuhito casereportondysgraphiainapatientreceivingblinatumomabcomplexcharactersareeasytofindinahandwritingtest AT fujimotoshino casereportondysgraphiainapatientreceivingblinatumomabcomplexcharactersareeasytofindinahandwritingtest AT takahashiyoshimitsu casereportondysgraphiainapatientreceivingblinatumomabcomplexcharactersareeasytofindinahandwritingtest AT kimurashiori casereportondysgraphiainapatientreceivingblinatumomabcomplexcharactersareeasytofindinahandwritingtest AT aijokeiko casereportondysgraphiainapatientreceivingblinatumomabcomplexcharactersareeasytofindinahandwritingtest AT takayanagimami casereportondysgraphiainapatientreceivingblinatumomabcomplexcharactersareeasytofindinahandwritingtest AT mizutashuichi casereportondysgraphiainapatientreceivingblinatumomabcomplexcharactersareeasytofindinahandwritingtest AT masaujitogen casereportondysgraphiainapatientreceivingblinatumomabcomplexcharactersareeasytofindinahandwritingtest AT masakiyasufumi casereportondysgraphiainapatientreceivingblinatumomabcomplexcharactersareeasytofindinahandwritingtest |